NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$13.42
-0.70 (-4.96%)
Close of Nov 06, 2026 · end-of-day data
IART 8-K filings in 2025
Every material Form 8-K Integra Lifesciences filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Integra LifeSciences adopted a change in control severance program on December 11, 2025, covering executives including CFO Lea Knight. The program takes effect January 1, 2026, and renews a program scheduled to expire December 31, 2025, and it pays severance only after a qualifying termination within two years of a change in control that occurs by December 31, 2026. The filing sets the benefit terms and does not describe any change in leadership.
Program adopted December 11, 2025, effective January 1, 2026, and renews a program due to expire December 31, 2025
Lump sum severance of 1.5 times salary plus target bonus, or 2 times for CFO Lea Knight, after a qualifying termination
Participants include Lea Knight (EVP and CFO), Robert T. Davis, Jr., Michael McBreen, and Harvinder Singh
Benefits include COBRA premium support for up to 18 months and outplacement services for up to 12 months
Integra reported third quarter 2025 revenue of $402.1 million, up 5.6% from a year earlier, and a GAAP net loss of $(5.4) million, or $(0.07) per diluted share, compared with a loss of $(0.14) per share a year earlier. Adjusted EPS rose to $0.54 from $0.41, but the company said two supply interruptions weighed on revenue and it revised its 2025 revenue guidance, with fourth-quarter reported revenue expected to decline year over year, which matters to shareholders weighing the outlook.
Q3 revenue of $402.1 million rose 5.6% reported and 5.0% organic; Codman Specialty Surgical was $292.6 million and Tissue Technologies was $109.5 million
GAAP net loss narrowed to $(5.4) million, or $(0.07) per diluted share, from $(10.7) million, or $(0.14), a year earlier; adjusted EPS was $0.54 versus $0.41
Full-year 2025 revenue guidance updated to $1.620 billion to $1.640 billion; adjusted EPS guidance of $2.19 to $2.24 for the full year
Fourth-quarter 2025 reported revenue expected at $420 million to $440 million, representing reported growth of (5.1%) to (0.6%)
Integra LifeSciences reported second-quarter 2025 revenue of $415.6 million, down 0.6% from a year earlier, and adjusted earnings of $0.45 per diluted share, versus $0.63 a year earlier. A $511 million goodwill impairment charge drove a GAAP net loss of $484.1 million, or $(6.31) per diluted share. The company updated its full-year revenue guidance to $1.655 billion to $1.680 billion and reaffirmed adjusted EPS guidance of $2.19 to $2.29.
Revenue $415.6 million, down 0.6% reported and 1.4% organic versus Q2 2024
GAAP net loss $484.1 million, or $(6.31) per diluted share, versus $(12.4) million a year earlier, mainly from the $511 million goodwill impairment
Adjusted EPS $0.45 versus $0.63; Q3 2025 adjusted EPS expected at $0.40 to $0.45
Net debt $1.59 billion at June 30, 2025; total leverage ratio 4.5x
On June 6, 2025, Integra LifeSciences amended its credit agreement to raise the maximum consolidated total leverage ratio it must maintain, from 5.00 to 1.00 through June 30, 2026, then stepping down to 4.00 to 1.00 from March 31, 2027. The amendment also temporarily restricts certain investments, incremental borrowing, liens, restricted payments and intellectual property transfers, and the company states it does not increase total indebtedness.
Amendment dated June 6, 2025, to the Seventh Amended and Restated Credit Agreement dated March 24, 2023.
Maximum leverage ratio is 5.00 to 1.00 for quarters ending March 31, 2025 through June 30, 2026, then 4.75 (September 30, 2026), 4.50 (December 31, 2026) and 4.00 (March 31, 2027 onward).
Through the Covenant Relief Period, which runs until delivery of fiscal 2026 financial statements, limits apply to investments, incremental debt, liens, restricted payments and intellectual property transfers.
The company states the amendment does not increase its total indebtedness.
Integra LifeSciences' board approved the transition of Dr. Stuart M. Essig from Executive Chairman to non-executive Chairman, effective July 1, 2025, and the filing says the change does not result from any disagreement with the company or board. At the May 9, 2025 annual meeting, stockholders elected all eight director nominees, approved a 2,200,000-share increase to the equity incentive plan, and ratified PricewaterhouseCoopers LLP as auditor for 2025.
Board approved Dr. Essig's move from Executive Chairman to non-executive Chairman, effective July 1, 2025.
The filing states the transition is not the result of any disagreement with the company or board on operations, policies or practices.
Stockholders approved Amendment No. 2 to the equity incentive plan, adding 2,200,000 shares: 69,088,553 for and 2,388,890 against.
All eight director nominees were elected; PricewaterhouseCoopers LLP was ratified for fiscal 2025 with 72,960,045 votes for.
Integra LifeSciences reported first-quarter 2025 results on May 5, 2025. Reported revenue rose 3.7% to $382.7 million, but organic revenue fell 3.5%, the GAAP net loss widened to $25.3 million, and adjusted earnings per diluted share fell to $0.41 from $0.55. The company reaffirmed its full-year revenue guidance but cut its full-year adjusted EPS guidance to $2.19 to $2.29, including an estimated $(0.22) per share impact from new tariffs.
Q1 revenue was $382.7 million, up 3.7% on a reported basis and down 3.5% on an organic basis.
GAAP net loss was $25.3 million, or $(0.33) per diluted share, versus a $3.3 million loss, or $(0.04), a year earlier.
Adjusted EPS was $0.41 versus $0.55; full-year adjusted EPS guidance was cut to $2.19 to $2.29.
Full-year 2025 revenue guidance of $1.650 billion to $1.715 billion was reaffirmed; second-quarter adjusted EPS is expected at $0.40 to $0.45.
Integra LifeSciences reported fourth-quarter 2024 revenue of $442.6 million, up 11.5% on a reported basis but up 3.5% on an organic basis, and adjusted earnings of $0.97 per diluted share versus $0.89. For full-year 2024 it posted a GAAP net loss of $6.9 million, or $(0.09) per diluted share, and adjusted earnings per share fell to $2.56 from $3.10, with 2025 adjusted EPS guided to $2.41 to $2.51.
Q4 2024 revenue $442.6 million, up 11.5% reported and 3.5% organic; GAAP EPS $0.25 in both Q4 2024 and Q4 2023
Full-year 2024 GAAP net loss $6.9 million, or $(0.09) per diluted share, versus GAAP net income of $67.7 million, or $0.84, in 2023
Full-year 2024 adjusted EBITDA $322.2 million, down $47.4 million; 2025 revenue guidance $1,650 million to $1,715 million
Q1 2025 adjusted EPS guidance $0.40 to $0.45; full-year 2025 adjusted EPS guidance $2.41 to $2.51
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Integra Lifesciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →